Phase II study of intravenous 6-thioguanine in patients with advanced gastric carcinoma.
Phase II study of intravenous 6-thioguanine in patients with advanced gastric carcinoma.
复制标题
晚期胃癌患者静脉注射 6-硫鸟嘌呤的 II 期研究。
DOI：
10.1007/bf00176979
复制
发表时间：
1991
影响因子：
3.4
通讯作者：
Krakoff,IH
中科院分区：
文献类型：
--
作者：
Ajani,JA;Pazdur,R;Winn,RJ;Abbruzzese,JL;Levin,B;Wiseman,C;Lenado-Lee,MA;Patt,YZ;Krakoff,IH
在一项II期研究中，18例晚期胃癌患者接受静脉注射6-硫鸟嘌呤治疗。起始剂量为55 mg/m2，每日1次，每次30分钟，连续5天，每5周重复一次疗程。中位数为2个疗程（范围1-4）。在18例患者中，17例有可测量的癌症和最佳随访，完全可评估反应。没有患者达到完全或部分缓解。1例患者对原发性胃癌有短暂的轻微反应（15周），但转移性癌没有变化。1例患者的可测量癌没有变化，其他15例患者在静脉注射6-硫鸟嘌呤时病情进展。骨髓抑制虽然频繁，但在这些剂量下是轻度至中度的，并没有导致显著的发病率。非血液学毒性也很轻微。我们的数据表明，在此方案下静脉注射6-硫鸟嘌呤对先前未经治疗的晚期胃癌患者无效。
In a phase II study, 18 patients with advanced gastric carcinoma were treated with intravenous 6-thioguanine. A 30-minute infusion of 55 mg/m2(starting dose) was administered once a day for 5 consecutive days, the courses being repeated every 5 weeks. A median of 2 courses (range, 1–4) was administered. Among the 18 patients, 17 having measurable cancer and optimum follow-up were fully assessable for response. None of the patients achieved a complete or partial response. One patient achieved a transient minor response (15 weeks) of the primary gastric carcinoma but the metastatic carcinoma was unchanged. One patient had no change in his measurable carcinoma, and the other 15 patients had progressive disease while receiving intravenous 6-thioguanine. Myelosuppression, although frequent, was mild to moderate at these doses and did not result in significant morbidity. Nonhematologic toxicities were also mild. Our data suggest that intravenous 6-thioguanine given at this schedule is ineffective in previously untreated patients with advanced gastric carcinoma.